Navigation Links
Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
Date:4/30/2012

ions of oligonucleotides targeting microRNAs for therapeutic applications. In April 2008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics with an initial focus on fibrosis.

For more information, please visit http://www.regulusrx.com. Regulus is also on YouTube at http://www.youtube.com/user/RegulusRx#p/f and on Twitter at www.twitter.com/regulusrx.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Isis', Alnylam's and Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Any statement describing Isis', Alnylam's or Regulus' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Such parties' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause their results to differ materially from those expressed or implied by such forw
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
4. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... New Jersey, November 26, Rosetta Genomics (Nasdaq: ... results on December 5, 2008, before the,U.S. markets open. ... webcast to discuss these results at 8:30 a.m. ET ... To access the live conference call, U.S. and ...
... MENLO PARK, Calif., Nov. 26 Evalve, Inc., ... percutaneous repair of cardiac valves,announced today that the ... MitraClip(R) system at the University of Hull, Castle ... is the first commercially,available medical device which provides ...
... 26 Aldrich, a division of,Sigma-Aldrich (Nasdaq: ... Science catalog. The catalog features more than 4,000 ... Ceramic Science,Nanomaterials, Micro/NanoElectronics and Polymer Science. Each chapter,contains ... advances,in these fields. , ...
Cached Biology Technology:Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 3Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research 2
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... A new report from the Institute of Medicine says ... at least 60 minutes of vigorous or moderate intensity ... half of American youth meet current evidence-based guidelines of ... physical activity daily, according to the report, which was ... for nearly half of their waking hours, the committee ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
... might one day avoid the prospect of invasive breast ... involve using stem cells derived from their own fat, ... potential these cells may have for regenerating new breast ... to prove that an injection of fat-derived stem cells ...
... bees, neuropeptides control brain activity and, hence, our behaviors. Understanding ... honey bee will assist researchers in understanding the roles they ... neurons in the brain of a honey bee (Apis mellifera), ... period at the end of this sentence. The activities of ...
... covering almost half the animal species on the planet has ... relationships between four major groups of insects. , ... related to beetles and more distantly related to bees and ... are published in the special Honey Bee Genome issue of ...
Cached Biology News:Fat stem cells being studied as option for breast reconstruction 2Scientists identify 36 genes, 100 neuropeptides in honey bee brains 2New genetic analysis forces re-draw of insect family tree 2
... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
... joined forces with the Mickle Laboratory Engineering ... Chopper. This tissue sectioning system has been ... metabolic experiments and to be especially applicable ... biopsy or from small organs. Its special ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... easy grip) Mfr Desig: ...
... fluorescence scanner with 1 or 2 color(s), ... CGH, ) spotted on standard slides combining ... scanners include three different models:, ... dual fluorescence scanner (635nm and 532nm). , ...
Biology Products: